Research Disclaimer
This article reviews published scientific literature for educational purposes only. All compounds referenced are sold by Blank Peptides exclusively for in-vitro research and laboratory use. Nothing in this article constitutes medical advice, a treatment recommendation, or an endorsement of human use.
Growth hormone secretagogues (GHS) work differently than exogenous growth hormone. They act on the pituitary’s own release machinery, so pulsatile secretion patterns and feedback regulation stay intact instead of being overridden by supraphysiological GH levels. That distinction has made GHS compounds central to research on muscle protein synthesis, body composition, and tissue recovery.
Pulsatile GH Release: Why It Matters
The anterior pituitary releases growth hormone in discrete pulses. Published work indicates that pulsed GH exposure drives downstream anabolic effects more effectively than continuous exposure:
- IGF-1 production: pulsatile exposure drives substantially higher IGF-1 output than continuous GH
- Satellite cells, the muscle stem cells that drive hypertrophy, respond preferentially to pulsed GH
- Receptor sensitivity holds up: continuous GH exposure downregulates receptors, while pulsed release does not
- Hypothalamic-pituitary regulation stays intact, which prevents GH excess
Ipamorelin: Selective Ghrelin Mimetic
Ipamorelin is a pentapeptide that activates the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by ghrelin. What distinguishes Ipamorelin in the published literature is its selectivity:
- GH release stimulation: strong and dose-dependent
- Cortisol: no meaningful alteration
- Prolactin: no meaningful alteration
- Aldosterone: no meaningful alteration
Most ghrelin mimetics trigger broader hormonal disruption. Ipamorelin’s narrower profile is why it appears so often in GH research protocols.
CJC-1295: GHRH Amplification
CJC-1295 is a modified GHRH analog. While Ipamorelin triggers GH pulses via the ghrelin pathway, CJC-1295 amplifies the GHRH signal, a mechanistically distinct and complementary approach.
- DAC variant: binds albumin, extending half-life to ~6-8 days. Sustained GH elevation with less frequent dosing
- No-DAC variant: clears faster, allowing more precise timing in research designs
Sermorelin: Three Decades of Published Data
Sermorelin (GRF 1-29) is the first 29 amino acids of endogenous GHRH. It has the longest published safety record of any GH secretagogue, having been used in clinical settings since the 1990s.
- Half-life ~10-20 minutes, producing precise, time-limited GH pulses
- Suited to acute research designs that need tight temporal control over GH elevation windows
Tesamorelin: Visceral Fat Specificity
Tesamorelin is a full-length GHRH analog (44 amino acids) with an unusual specificity profile:
- Selective visceral fat reduction: published clinical trial data shows targeted reduction without significant subcutaneous fat loss
- Applications in metabolic syndrome and body composition research
- Cognitive function improvements turned up as a secondary finding and have opened a separate research track
BPC-157 and TB-500: The Recovery Side
Muscle growth research is incomplete without addressing recovery. These two peptides approach tissue repair through complementary mechanisms:
- BPC-157: 15-amino acid peptide with 180+ PubMed-indexed publications documenting effects on tendon repair, angiogenesis, and mucosal protection
- TB-500: fragment of Thymosin Beta-4 that upregulates actin and promotes cellular migration to injury sites
MOTS-c: Mitochondrial Performance
MOTS-c is a mitochondrial-derived peptide that activates AMPK, the same cellular energy sensor activated by physical exercise:
- Improved endurance capacity documented in published animal models
- Better glucose metabolism and fuel efficiency at the cellular level
- Faster restoration between exercise bouts
As a naturally occurring peptide encoded in mitochondrial DNA, MOTS-c sits on a different axis from the GH-pathway compounds, acting on cellular energy signaling instead of hormone release.
Browse These Compounds
IpamorelinCJC-1295 DACCJC-1295 no DACSermorelinTesamorelinBPC-157TB-500MOTS-CIpamorelin/CJC-1295
Written by Blank Peptides Research Team
Peptide science researchers with 5+ years in US-based peptide manufacturing, independent HPLC and mass spectrometry testing, and research education. All content is reviewed for scientific accuracy before publication.
REVIEWED BY
Dr. Tobias S — PhD Chemist, Peptide and Unnatural Amino Acid Synthesis
Dr. Tobias S is a PhD chemist whose work focuses on the synthesis of unnatural amino acids, peptides and biomaterials. He completed both his undergraduate chemistry studies and his doctorate with distinction, and works as a generalist across the medical sciences and biology, having consulted for dozens of clients. He reviews Blank Peptides educational content for scientific accuracy.
Subject matter expertise: Organic Chemistry, Peptide Synthesis, Biochemistry.
